Baidu
map

心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JACC：阿利库单抗能减少急性冠脉综合征患者不良事件的发生

2019-01-29 MedSci MedSci原创

心血管阿利库单抗冠心病
关注

ODYSSEY OUTCOMES 临床研究旨在18924名急性冠脉综合征（ACS）患者中比较阿利库单抗和安慰剂联合高强度或最大耐受的他汀类药物治疗的效果，发现阿利库单抗可以减少主要终点事件和全因死亡的发生。本研究的目的旨在探究ODYSSEY OUTCOMES 临床研究中阿利库单抗能减少总体非致死性心源性死亡和全因死亡的程度。在3064例新发事件和5425例总体不良事件中，阿利库单抗组患者的新发非致

ODYSSEY OUTCOMES 临床研究旨在18924名急性冠脉综合征（ACS）患者中比较阿利库单抗和安慰剂联合高强度或最大耐受的他汀类药物治疗的效果，发现阿利库单抗可以减少主要终点事件和全因死亡的发生。本研究的目的旨在探究ODYSSEY OUTCOMES 临床研究中阿利库单抗能减少总体非致死性心源性死亡和全因死亡的程度。

在3064例新发事件和5425例总体不良事件中，阿利库单抗组患者的新发非致死性心源性事件和总体非致死性心源性事件分别减少190和385例。阿利库单抗能减少总体非致死性心源性事件（HR：0.87； 95% cl： 0.82-0.93）和死亡事件（HR：0.83； 95% cl： 0.71-0.97），另外，阿利库单抗在非致死性和致死性事件风险之间有很强的相关性。

研究结果显示，在急性冠脉综合征患者中，阿利库单抗减少的总体心血管不良事件是新发心血管不良事件的两倍，因此，总体心血管事件的发生更能反映阿利库单抗的临床疗效。

原始出处：

本文系梅斯医学(MedSci)原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854298, encodeId=bf4818542982b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Oct 16 03:00:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066160, encodeId=33332066160e4, content=<a href='/topic/show?id=2e8a9e7241a' target=_blank style='color:#2F92EE;'>#阿利库单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97724, encryptionId=2e8a9e7241a, topicName=阿利库单抗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Fri Mar 08 08:00:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326113, encodeId=ac441326113d9, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jan 31 05:00:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431426, encodeId=304514314267a, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 31 05:00:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-10-16 hbwxf

    #JACC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1854298, encodeId=bf4818542982b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Oct 16 03:00:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066160, encodeId=33332066160e4, content=<a href='/topic/show?id=2e8a9e7241a' target=_blank style='color:#2F92EE;'>#阿利库单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97724, encryptionId=2e8a9e7241a, topicName=阿利库单抗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Fri Mar 08 08:00:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326113, encodeId=ac441326113d9, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jan 31 05:00:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431426, encodeId=304514314267a, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 31 05:00:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-03-08 小华子

    #阿利库单抗#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1854298, encodeId=bf4818542982b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Oct 16 03:00:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066160, encodeId=33332066160e4, content=<a href='/topic/show?id=2e8a9e7241a' target=_blank style='color:#2F92EE;'>#阿利库单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97724, encryptionId=2e8a9e7241a, topicName=阿利库单抗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Fri Mar 08 08:00:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326113, encodeId=ac441326113d9, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jan 31 05:00:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431426, encodeId=304514314267a, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 31 05:00:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-01-31 12498568m50暂无昵称

    #ACC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1854298, encodeId=bf4818542982b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Oct 16 03:00:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066160, encodeId=33332066160e4, content=<a href='/topic/show?id=2e8a9e7241a' target=_blank style='color:#2F92EE;'>#阿利库单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97724, encryptionId=2e8a9e7241a, topicName=阿利库单抗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Fri Mar 08 08:00:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326113, encodeId=ac441326113d9, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jan 31 05:00:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431426, encodeId=304514314267a, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 31 05:00:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-01-31 zhouqu_8

    #综合征#

    0

相关资讯

JAHA：抽烟会增加外周动脉疾病风险

与非西班牙裔的白种人相比，黑种人的外周动脉疾病（PAD）发病率要明显更高，但是抽烟在黑种人的PAD发生中的影响尚不清楚。本研究的目的旨在评估抽烟对黑种人PAD发生的影响。本研究纳入了JHS临床研究中的5306名黑种人，根据自我报告将研究对象分为现在抽烟、以前抽烟（至少400支）和从不抽烟，分析结果显示，有3579名（68%）研究对象从不抽烟，986名（19%）过去抽烟，693名（13%）现在抽烟，

JAHA：颈总动脉超声灰度特征可预测心血管疾病发生风险

本研究的目的旨在评估颈总动脉回声和灰度纹理特征的测量是否与心血管疾病危险因素相关，且是否能预测心血管疾病的发生。本研究纳入了MESA 临床研究中的1788名参与对象，并对其颈总动脉的4个灰度指标进行了超声测量，参与者的平均年龄为63.1岁，女性占52.6%，白种人占32.1%，黑种人占27.8%，西班牙人占23.3%，中国人占16.8%。经过平均13年时间的随访，共有283例冠心病事件，120例卒

BMJ：油炸食物与全因、心血管及肿瘤死亡风险

研究认为，油炸食品，特别是炸鸡和炸鱼类，导致女性全因死亡及心血管死亡风险增加

JAHA：高血钾症伴Brugada 表型患者的临床特征研究

严重的代谢紊乱也可引起Brugada 综合征样的心电图，成为Brugada 样表型（BrPh），本研究的目的旨在评估BrPh患者的临床特征和预后，并阐明BrPh致高血钾症的原理。本研究纳入分析了15例高血钾症伴BrPh患者的临床特征和预后，并将其与高血钾症不伴BrPh患者进行比较。在6年随访的这段时间里，15名高血钾症伴BrPh患者均可以因血钾水平正常后症状消失。6名患者（40%）表现为恶性心律失

JACC：慢性肾脏疾病可增加主动脉狭窄风险！

慢性肾脏疾病（CKD）和主动脉狭窄（AS）有许多共同的危险因素。本研究的目的旨在评估肾功能不全是否与AS的发展相关。本研究纳入了SCREAM 研究中的1121875名无AS诊断的城市居民，平均年龄为50岁（IQR：36-64岁），女性占54%，平均估计肾小球滤过率（eGFR）为96 ml/min/1.73 m2 （IQR：82 - 109 ml/min/1.73 m2），有66949名（6%）对象

JAHA：慢性肾脏疾病合并主动脉狭窄患者的预后研究

本研究的目的旨在评估主动脉狭窄（AS）伴慢性肾脏疾病（CKD）患者的长期生存率。本研究纳入了2005-2012年的839名AS合并CKD的患者（平均年龄78±9 岁，男性占51%），患者长期的全因死亡率和心源性死亡率是与CKD不合并AS的患者进行比较。最终，共有511 (61%)、252 (30%)和76 (9%)名患者发展为CKD3a期、3b期和4期，93%的患者患有高血压，28%的患者患有糖尿

Baidu
map
Baidu
map
Baidu
map